Latest news with #PalamurBiosciencesPvt.Ltd
Hans India
20-06-2025
- Health
- Hans India
Palamur Biosciences Faces Scrutiny Amid PETA Allegations, Awaits Official Inspection Report
Mahabubnagar: Palamur Biosciences Pvt. Ltd. (PBS), a leading preclinical research facility in Mahabubnagar, has recently come under public scrutiny following complaints submitted by PETA India. The allegations, reportedly based on claims from a former employee, were widely circulated before PBS was given an opportunity to present its side. In response, a multi-agency inspection involving the Committee for the Purpose of Control and Supervision of Experiments on Animals (CCSEA) and the Animal Welfare Board of India has thoroughly reviewed PBS operations. The organization is now awaiting the committee's official findings. Despite the controversy, PBS maintains that it operates with full regulatory compliance and transparency. Recognized by international and national bodies such as GLP, CDSCO, AAALAC, and OLAW, PBS has been a cornerstone of India's biomedical innovation ecosystem for over 15 years. It is the country's only large-animal testing facility and one of the few in Southeast Asia, playing a vital role in the development of pharmaceuticals, medical devices, vaccines, and agrochemicals. PBS is also home to India's first large-animal-based medical device evaluation center, supported by BIRAC under the 'Make in India' and 'Atmanirbhar Bharat' initiatives. It has validated breakthrough technologies such as artificial hearts, dialysis systems, heart valves, and stents—contributing significantly to India's healthcare advancement. The Directors of PBS emphasized their commitment to ethical research, scientific excellence, and animal welfare, stating, 'We are confident the inspection will confirm our long-standing adherence to the highest standards. Baseless allegations can severely harm India's R&D ecosystem, especially startups that rely on domestic preclinical services.' PBS has urged media, regulators, and the public to await the official report and engage in discourse based on facts, not speculation, to protect the integrity of India's innovation landscape.
Hans India
17-06-2025
- Health
- Hans India
Animal Protection Organisations Urge Immediate Closure of Palamur Biosciences for Systemic Animal Cruelty and Regulatory Violations
New Delhi: Twenty leading animal protection organisations, who are members of the Federation of Indian Animal Protection Organisations (FIAPO), India's largest network of animal protection groups, have submitted an urgent appeal to the Committee for the Control and Supervision of Experiments on Animals (CCSEA) seeking the permanent closure of Palamur Biosciences Pvt. Ltd. for egregious animal cruelty and repeated regulatory violations. Speaking on behalf of the federation, Bharati Ramachandran, CEO of FIAPO, stated: "We urge the CCSEA to uphold its mandate and act without delay to end the suffering of animals at Palamur Biosciences. The egregious violations reported are not isolated incidents—they represent a complete breakdown of ethics and compliance in animal-based research. We must ensure that cruelty is not the cost of scientific progress." Palamur Biosciences, located in Bhoothpur Mandal, Mahabubnagar, Telangana, has been engaging in severe and systemic mistreatment of animals in violation of national laws and scientific ethics. Video and photographic evidence reveal the following violations: · Severe overcrowding: Close to 1,500 dogs were confined in facilities designed to house no more than 800, resulting in heightened aggression, injuries, and unaddressed trauma. · Unregulated breeding: Dogs were bred excessively and continuously, from 18 months of age to nearly 13 years old, without appropriate rest periods between pregnancies, violating breeding norms. · Inhumane handling: Animals were routinely subjected to rough handling during procedures, with no evidence of pain mitigation. Documented instances include dogs being forcibly confined and injected with painful substances. · Non-compliant euthanasia methods: Euthanasia was conducted without sedation, in direct contravention of CCSEA guidelines. · Unlawful use and transport of primates: Rhesus macaques were reportedly used and transported in violation of regulatory requirements, posing serious public health risks. · Unauthorised breeding and inadequate housing of minipigs: Göttingen minipigs were bred without valid licensing and confined in conditions that lacked required environmental enrichment, breaching both national standards and OECD Good Laboratory Practice principles. These actions constitute clear violations of multiple statutory and regulatory frameworks, including the Prevention of Cruelty to Animals Act, 1960; Breeding of and Experiments on Animals Rules, 1998; Guidelines on the Regulation of Scientific Experiments on Animals, 2007; CPCSEA Guidelines for Laboratory Animal Facility, 2015; Bharatiya Nyaya Sanhita, 2023; OECD Good Laboratory Practice standards; and Medical Devices Rules, 2017. The organisations have called on the CCSEA to take the following actions immediately: 1. Revoke all existing CPCSEA registrations, approvals, and breeding licenses issued to Palamur Biosciences Pvt. Ltd. 2. Instruct the company to cease all ongoing experiments and permanently prohibit future applications involving the use of live animals. 3. Initiate immediate rehabilitation and relocation of all surviving animals in collaboration with reputable sanctuaries and rehoming networks.
